Golimumab Biosimilar is a monoclonal antibody commercialized by Teva Pharmaceutical Industries, with a leading Phase III program in Rheumatoid Arthritis. According to Globaldata, it is involved in 2 clinical trials, of which 1 was completed, and 1 is ongoing. GlobalData uses proprietary data and analytics to provide a complete picture of Golimumab Biosimilar’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.
The revenue for Golimumab Biosimilar is expected to reach an annual total of $61 mn by 2028 globally based off GlobalData’s Revenue Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.
Golimumab Biosimilar Overview
Monoclonal antibody is under development for the treatment of inflammation, rheumatoid arthritis and musculoskeletal diseases. The drug candidate is a biosimilar. It is developed based on SmartFactory GMP manufacturing platform. It is administered through subcutaneous and intravenous route.
Teva Pharmaceutical Industries Overview
Teva Pharmaceutical Industries (Teva) discovers, develops, manufactures, and commercializes generic and specialty medicines. The company provides specialty medicines to treat disorders of the central nervous system (CNS), cancer, respiratory, dermatology, women’s health, and other disease conditions. It offers generic medicines in a range of dosage forms including capsules, tablets, injectables, liquids, inhalants, creams, and ointments. Teva also provides over-the-counter (OTC) products, besides active pharmaceutical ingredients (APIs). It also focuses on developing generic drugs. The company conducts its worldwide operations through a network of subsidiaries in regions such as North America, Europe, and International Markets. Teva is headquartered in Tel Aviv, Israel.
For a complete picture of Golimumab Biosimilar’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.